Whalesbook
Q4 Ka Dhamaka: International Sales Ki Badi Jeet!
Toh bhaiyon aur behno, Emcure Pharma ne Q4 mein kamaal kar diya! International markets mein inki sales 25.7% bhaag gayi aur ₹1,493 crore tak pahunch gayi. Yehi woh main reason hai jisne company ke overall profit ko 24% badha kar ₹243.74 crore kar diya. Over all revenue bhi 16.7% badh kar ₹2,469.7 crore ho gaya.
Domestic Market Mein Thodi Sasti?
Par bhai, ek taraf jahan international market mein party chal rahi thi, wahan domestic market mein thoda slow down dikha. Yahan sales sirf 5.2% badhi aur ₹977 crore tak pahunchi. Company keh rahi hai ki Zuventus ke portfolio aur internal reorganisation ki wajah se aisa hua.
Full Year Bhi Solid Raha!
Poore saal ki baat karein toh, FY26 mein Emcure ka net profit ₹941.27 crore raha aur revenue ₹9,203.54 crore kamaya. Ye unke paanch saal ke strategic plan ka pehla saal tha, aur company $1 billion revenue cross karne mein bhi kamyaab rahi.
Aage Kya? R&D Par Focus!
Future ki baat karein toh, company complex injectables aur biosimilars jaise R&D projects par khoob paisa laga rahi hai, jisse future mein aur growth mil sake.
Brokerage Kya Kehte Hain? Valuation Ka Kya Scene?
Ab valuation ki baat karein toh, Emcure ka P/E ratio lagbhag 35.6x se 53x ke beech mein hai. Ye thoda zyada hai Dr. Reddy's (~19.5x) aur Cipla (~23.18x) ke comparison mein, lekin Sun Pharma se kam hai (~39.78x). Lekin analysts kaafi positive hain aur is stock ko 'Strong Buy' keh rahe hain, jiska target price ₹1,780 se ₹1,795 ke beech mein de rahe hain.
Risks Bhi Hain Bhai!
Par sab kuch itna smooth nahi hai. Domestic business mein Zuventus portfolio ko lekar challenges hain, competition aur pricing pressure bahut zyada hai. Company ne Zuventus band hone ki rumor ko competitor sabotage bataya hai. Aur haan, company ka record regulatory issues se bhi juda raha hai, jaise US FDA ki warning letter 2016 mein aur US mein generic drug price fixing investigations. Yeh sab factors aur premium valuation ko dekh kar investors ko thoda caution rehna padega, agar domestic performance sudhra nahi toh.
Future Growth Aur Leadership Continuity
Aage badhne ke liye, Emcure R&D par focus karegi, especially complex injectables aur biosimilars mein. CEO Satish Mehta ne kaha hai ki company industry average se zyada sustainable growth aur margin expansion ke liye committed hai. Board ne FY26 ke liye ₹3.6 per share ka final dividend bhi recommend kiya hai. Aur shareholders Satish Mehta ko MD ke roop mein paanch saal ke liye dobara appoint karne par bhi vote karenge, jisse leadership mein continuity bani rahegi.